DXR· Health Care› Medical Instruments & Supplies

Daxor Corporation

Stage 1 · Basing · week 8

As of Oct 22, 2026, Daxor is in Stage 1, the basing phase, now in week 8 (since Sep 1, 2026). It closed at $9.40, 36.3% below its 52-week high and below its 200-day average, which is falling.

Daxor Corporation engages in medical instrumentation and biotechnology operations. More about the company

$9.40

-3.79% today

$54.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is DXR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S4 21w

S2 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 2w → S1 4w → S4 15w → S1 9w → S4 5w → S1 2w → S2 8w → S3 9w → S4 2w → S3 1w → S4 1w → S1 5w → S2 6w → S4 21w → S1 8w → S2 31w → S3 7w → S4 12w → S1 8w → S4 2w → S1 7w current

Total tracked: 166 weeks across 21 stage runs.

DXR among Medical Instruments & Supplies36th of 51 by relative strength

All 51 →

Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	PLSEPulse Biosciences, Inc	Stage 2 · wk 34	98	+1.3%
2	PDEXPro-Dex, Inc.	Stage 2 · wk 36	97	−13.3%
3	HBIOHarvard Bioscience, Inc.	Stage 2 · wk 11	95	+3.6%
4	ATRCAtriCure, Inc.	Stage 2 · wk 10	89	−1.1%
5	WSTWest Pharmaceutical Services, Inc.	Stage 2 · wk 24	82	+4.8%
6	BDXBecton, Dickinson and Company	Stage 2 · wk 11	81	+9.8%
7	ICUIICU Medical, Inc.	Stage 3 · wk 1	81	+3.1%
8	OSUROraSure Technologies, Inc.	Stage 3 · wk 8	75	−4.8%
…36	DXRDaxor Corporation	Stage 1 · wk 8	33	−13.1%

vs 52W High

-36.3%

$8.87 lo$14.75 hi

36.3% below 52W high, far from high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 8

1w13w26w

Week 8, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-13.5%

200 DMA: $10.87 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.66x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.1%

-10.0%

-3.8%

YTD

-34.5%

-30.6%

Scan Membership

Breakout Watch

Latest: 2024-11-01

8 appearances in last 60 days. First seen: 2018-12-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 8 · Vol 0.66x

2026-10-21S1

Wk 8 · Vol 0.46x

2026-10-20S1

Wk 7 · Vol 0.12x

2026-10-19S1

Wk 7 · Vol 0.34x

2026-10-16S1

Wk 7 · Vol 0.20x

2026-10-15S1

Wk 7 · Vol 1.09x

2026-10-14S1

Wk 7 · Vol 0.70x

2026-10-13S1

Wk 6 · Vol 0.90x

2026-10-12S1

Wk 6 · Vol 0.22x

2026-10-09S1

Wk 6 · Vol 0.35x

2026-10-08S1

Wk 6 · Vol 0.16x

2026-10-07S1

Wk 6 · Vol 0.34x

Moving averages & range

50 DMA

$10.58

200 DMA

$10.87

52W High

$14.75

52W Low

$8.87

5D Low

$9.40

Resistance levels (recent highs)

20d High

$11.70

60d High

$11.72

120d High

$11.72

250d High

$14.75

Next resistance

+24.5%

to 20d High

P/E (TTM)

8.6

Forward —

ROE

+14.2%

Profit margin +19861.4%

Dividend Yield

0.00%

P/B 1.1

Daxor: quick answers

What stage is Daxor in?

As of Oct 22, 2026, Daxor (DXR) is in Stage 1, the basing phase. It entered Stage 1 on Sep 1, 2026 and is in week 8. What the four stages mean

Is Daxor in an uptrend?

Not yet. Daxor is in Stage 1, a base that can come before an uptrend. It trades 13.5% below its 200-day average, which is falling.

How far is Daxor from its 52-week high?

Daxor closed at $9.40 on Oct 22, 2026, 36.3% below its 52-week high of $14.75. Its 52-week low is $8.87.

How has Daxor performed over the past year?

As of Oct 22, 2026, Daxor is down 30.6% over the past year and down 34.5% so far in 2026.

Which sector and industry is Daxor in?

Daxor is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.